Drug survival ‘poor’ for most patients on thalidomide
The exception appears to be treatment for actinic prurigo, Melbourne dermatologists say
Most patients prescribed thalidomide for a dermatological condition other than actinic prurigo cease the therapy within two years, according to an Australian case series.
Victorian dermatologists describe outcomes for 28 dermatology patients treated with thalidomide at a large Melbourne hospital in a research letter to the Australasian Journal of Dermatology.
